PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
|
|
- Maud Bennett
- 5 years ago
- Views:
Transcription
1 PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer Research Center Seattle, Washington
2 Outline PET-adapted strategies in advanced stage HL PET-adapted strategies in early stage HL The future is coming? Brentuximab vedotin in upfront treatment of advanced HL
3 Outline PET-adapted strategies in advanced stage HL PET-adapted strategies in early stage HL The future is coming? Brentuximab vedotin in upfront treatment of advanced HL
4 Hodgkin Lymphoma Expected outcomes and goals of therapy in 2017 Stage Early stage favorable (Stage I-II) Early stage unfavorable (stage I, II with risk factors*) Advanced stage (bulky, IIB, III, IV) % Cured with primary therapy Therapeutic Priority 90 Reduce Toxicity Increase Efficacy 75 Increase Efficacy * Large mediastinal mass, extranodal extension, 3 nodal sites, elevated ESR; age 50, MC histology Adapted from slide courtesy of Ranjana Advani
5 Advanced HL: Chemotherapy ABVD x 6 cycles considered standard of care in North America Gordon LI, et al. J Clin Oncol 31:684-91, 2013
6 Advanced HL: Chemotherapy escbeacopp x 6 cycles considered standard of care in Europe (GHSG) Time (months) Engert A, et al. Lancet 379:1791-9, 2012
7 Importance of long term follow-up: HD2000 ABVD x 6 vs. escbeacopp x 4 + BEACOPP baseline x 2 Median follow up 10 years OS Secondary Malignancies PFS Merli F, Luminari S, Gobbi PG, et al:. J Clin Oncol, 2015
8 Increased risk of sterility with BEACOPP Amenorrhea 6-8 cycles escbeacopp 2+2 Behringer K, et al. J Clin Oncol 31:231-9, 2013
9 escbeacopp is not for everyone Treatment-related mortality risk score Points Age PS 0 < Wongso D, et al. J Clin Oncol 31: , 2013
10 Negative interim PET after 2 cycles of ABVD associated with significantly improved PFS Prognosis independent of IPS at diagnosis Gallamini et al. J Clin Oncol 25: , 2007
11 Can treatment decisions be made based on interim-pet? Should therapy be escalated with a positive interim-pet (PET2)? Should therapy be de-escalated with a negative PET2? Does this have the potential to improve outcomes?
12 Initial treatment Trial # of patients Stage PET-adapted treatment HD IIB-IV vs. R-4+4 ABVD x 2 escbeacopp x 2 Gallamani et al. SWOG 0816 Press et al. RATHL Johnson et al. HD 0801 Zinzani et al. AHL 2011 Casasnovas et al. HD18 Borchman et al. - ABVD x III-IV + escbeacopp x 6 - ABVD x II-IV + escbeacopp x 6 or BEACOPP-14 x 8 - ABVD x 4 vs. AVD x IIB-IV + IGEV + auto HSCT - ABVD x IIB-IV + escbeacopp x 4 - escbeacopp x 4 vs. ABVD x IIB-IV + escbeacopp x 6 vs. R-escBEACOPP x 6 - escbeacopp x 4 vs. escbeacopp x 2 Adapted from Lynch RC, Advani RH, ASCO Education Book 2016
13 RATHL Trial: Study design Stage IIA with bulk and/or 3 sites Stage IIB-IV Radiotherapy at MD discretion Characteristic Number or % Median age 33 (18-79) Male 55% Stage II III IV 41% 31% 28% B symptoms 61% Bulky disease 31% PS % IPS % 49% 18% Johnson P, et al. N Engl J Med 374: , 2016
14 RATHL Trial: Study design Stage IIA with bulk and/or 3 sites Stage IIB-IV Goals Assumptions: Johnson P, et al. N Engl J Med 374: , 2016 Characteristic Number or % Median age 33 (18-79) Male 55% Stage II III IV 41% 31% 28% B symptoms 61% Bulky disease 31% 75% PET-2 negative; 3-yr PFS 95% in PET-2 negative patients Non-inferiority design 90% power to exclude AVD being > 5% worse Radiotherapy at MD discretion PS % IPS Statistics: 1200 pts and 3 years follow-up; primary endpoint 3-yr PFS 34% 49% 18%
15 RATHL Trial: Results in PET2 negative patients Median follow up 41 months ITT analysis HR 1.13 ( , p=0.48) ABVD 3-year PFS 85.7% (82.1%-88.6%) AVD 3-year PFS 84.4% (80.7%-87.5%) Difference 1.6% (-3.2% to 5.3%) 3-year OS ABVD 97.2% (95.1 to 98.4) AVD 97.6% (95.6 to 98.7) No statistical difference in 3-year PFS and OS Just outside pre-determined non-inferiority margin of 5%
16 RATHL Trial: Results Increased toxicity in BEACOPP arms Grade 3/4 AE ABVD, Cycles 1 and 2 (n = 1203) ABVD, Cycles 3-6 (n = 468) AVD, Cycles 3-6 (n = 457) BEACOPP-14 (n = 94) Neutropenia 695 (58%) 275 (59%) 269 (59%) 59 (63%) 52 (67%) Thrombocytopenia 16 (1%) 6 (1%) 15 (3%) 18 (19%) 33 (42%) Any infection 76 (6%) 68 (15%) 47 (10%) 35 (37%) 33 (42%) Febrile neutropenia 24 (2%) 22 (5%) 10 (2%) 10 (11%) 20 (26%) Any pulmonary event 8 (1%) 15 (3%) 3 (1%) 4 (4%) 4 (5%) Any grade 3/4 AE 771 (64%) 322 (69%) 299 (65%) 75 (80%) 65 (83%) escbeacopp (n = 78) Johnson P, et al. N Engl J Med 374: , 2016
17 RATHL trial: Results in PET2 positive patients PET2+ Group 3-year PFS 67.5% (95% CI, 59.7 to 74.2), PET2+ Group 3-year OS 87.8% (95% CI, 81.5 to 92.1) Improved PFS in PET2 positive patients compared to historical controls Johnson P, et al. N Engl J Med 374: , 2016
18 RATHL trial: Results Risk factor Number (%) 3-year PFS Bulk Present 119 (34.7%) 91.5 ( ) Absent 224 (65.3%) 91.7 ( ) B symptoms Present 206 (59.4%) 92.0 ( ) Absent 141 (40.6%) 90.6 ( ) B symptoms or bulk Present 257 (74.5%) 90.9 ( ) Absent 88 (25.5%) 94.1 ( ) 348 total stage II patients were PET2 negative and did not receive radiotherapy Similar 3-year PFS in patients with or without bulk Johnson P, et al. N Engl J Med 374: , 2016
19 HD0801: Study design PET-2 neg ABVD x2 PET-2 pos Stage IIB-IV IPS 0-7 Characteristic Number or % Median age 33 (18-68) Male 54% ABVD x4 IGEV Salvage IPS % 44% PET neg BEAM-Auto PET pos Allo if matched donor, Auto if no matched donor PS Stage II III IV 66% 28% 6% 19% 35% 46% B symptoms 64% Bulk 35% Zinzani PL, et al. J Clin Oncol 34: , 2016
20 HD0801: Results PFS in PET2 positive patients similar to PET2 negative patients ITT 2-year PFS PET2-neg 81% (95% CI, 76% to 84%) PET2-pos 76% (95% CI, 66% to 84%) Per protocol PET2-pos 74% (95% CI, 62% to 82%) Median follow up 25 months 20/101 patients in PET2 pos group did not receive IGEV salvage/transplant
21 Summary: PET-adapted trials in advanced HL Results of escalation/de-escalation strategies are similar PET2 negative rate ~80% in most studies after ABVD x2 Bleomycin can be safely omitted with negative PET2 Some treatment failures seen even in PET2-negative patients Intensification of therapy to escbeacopp with positive PET2 may improve outcome over historical results with ABVD No control arm with continuing with ABVD Increased toxicity issues
22 Outline PET-adapted strategies in advanced stage HL PET-adapted strategies in early stage HL The future is coming? Brentuximab vedotin in upfront treatment of advanced HL
23 RAPID trial PET adapted elimination of XRT in early stage HL Deauville 1-2 * No difference in OS Radford J et al: N Engl J Med 372: , 2015
24 EORTC H10 Interim analysis finds increased events in PET-negative experimental arm Early stage favorable PET2 negative Early stage unfavorable PET2 negative PET-negative experimental arm closed by independent data monitoring committee Andre MPE, et al. J Clin Oncol 35: , 2017
25 Early stage favorable HL- abbreviated chemo plus radiation GHSG HD10 trial ABVD X Gy IFRT = ABVD X Gy IFRT GHSG unfavorable criteria ESR > 50, > 30 if B symptoms MMR > 0.33 More than 2 nodal sites Any E lesion Engert A, et al: N Engl J Med 363:640-52, 2010
26 Take home points early stage HL Very favorable early HL patients have excellent outcomes with abbreviated chemo/rt PET can identify low risk population that may do well without radiation However, there is a small benefit to radiation in preventing relapse Requires personalized treatment decision (patient preference, age, gender, sites of disease)
27 Outline PET-adapted strategies in advanced stage HL PET-adapted strategies in early stage HL The future is coming? Brentuximab vedotin in upfront treatment of advanced HL
28 Brentuximab vedotin Anti-CD30 antibody-drug conjugate FDA approved Relapsed HL after auto HSCT Failure of 2 regimens in patients not eligible for transplant Consolidation for high risk HL patients after auto HSCT Relapsed ALCL???Untreated Advanced HL??? Deng C, et al. Clin Cancer Res 19:22-7, 2013
29 Brentuximab active in patients who relapsed after autologous transplant 5 year end of study analysis 9% (9/100) of patients achieved sustained CR without additional therapy Chen R, et al: Blood 128:1562-6, 2016
30 Characteristic Number or % Median age Age 45 Age 60 Male 58% Stage III IV 36 (18-83) 34% 14% 36% 64% Connors et al. ASH 2017
31 A+AVD associated with prolonged 2-year PFS vs. ABVD PFS favoring A-AVD (HR [95% CI ]; p=0.035) 2 year PFS by independent review A-AVD: 82.1% (95% CI ) ABVD: 77.2% (95% CI ) Sub-group analysis favors A-AVD, data to be presented at ASH Connors et al. ASH 2017
32 A-AVD associated with higher rates of toxicity A-AVD: 7/9 on study deaths due to neutropenia (no primary GCSF)in the A+AVD arm were associated with neutropenia ABVD: 11/13 on study deaths due to pulmonary toxicity Protocol later amended to give A- AVD patients primary GCSF (n=83) Febrile neutropenia reduced from 19% to 11% Grade 3 infections reduced from 18% to 11%. Toxicity A-AVD ABVD Neutropenia 58% 45% Febrile neutropenia Grade 3 infection Peripheral neuropathy Peripheral neuropathy grade 3 Pulmonary toxicity grade 3 19% 8% 18% 10% 67% 43% 11% 2% 1% 3% Connors et al. ASH 2017
33 Special Issues!!! No bone marrow biopsy needed at diagnosis if PET used for staging Avoid growth factors with ABVD due to increased risk of pulmonary toxicity (no primary use) No dose delays with ABVD due to neutropenia treat on time with standard doses. Inferior outcomes with decreased dose intensity. Consider prophylactic antibiotics Repeat biopsy with refractory disease or relapse prior to starting subsequent therapy.
34 Questions? Thank you!
35 Hodgkin lymphoma staging Stage I II III IV Definition single lymph node or extranodal site two or more involved lymph node regions on the same side of the diaphragm lymph node involvement on both sides of the diaphragm presence of diffuse or disseminated involvement of one or more extralymphatic organs A absence of B symptoms B Presence of B symptoms Stage I-II Early stage Favorable Unfavorable Stage III-IV - Advanced stage Risk stratified by International Prognostic Score (IPS)
36 NCCN Guidelines, Hodgkin Lymphoma, Version Unfavorable Criteria
37 IPS: risk stratification for advanced HL Remains prognostic in ABVD era Serum albumin <4 g/dl Hemoglobin <10.5 g/dl Male gender Age >45 years Stage IV disease White blood cell count 15,000/microL Absolute lymphocyte count <600/uL and/or <8 percent of the total white blood cell count. Moccia et al. J Clin Oncol 30:3383-8, 2012
38 Advanced stage HL results: ABVD vs. BEACOPP Treatment 5-y PFS Diff. (%) 5-y OS Diff. (%) Reference ABVD x HD2000: Federico et al, JCO 2009 IPS 0-7 ABVD x Viviani et al, NEJM IPS 3 ABVD x EORTC 20012: Carde et al, JCO 2016 IPS 3 ABVD x LYSA H34: Mounier et al, Ann Oncol 2014 IPS 0-2 *Statistically significant Adapted from slide courtesy of Ranjana Advani = 4 escbeacopp + 4 BEACOPP baseline = 4 escbeacopp + 2 BEACOPP baseline
39 EORTC H10 Interim analysis finds increased events in PET-negative experimental arm PET2 positive All early stage PFS PET2 positive All early stage PFS PET-negative experimental arm closed by independent data monitoring committee Andre MPE, et al. J Clin Oncol 35: , 2017
40 Background Classical Hodgkin lymphoma (CHL) represents ~ 10% of all lymphomas 9000 new cases annually in the United States Highly curable with frontline therapy (chemotherapy +/- RT) Early stage > 90% Advanced stage ~ 80%
41 US Intergroup S0816 trial: Study design Advanced HL Stage III-IV IPS 0-7 Characteristic Number (%) Median age 32 (18-60) Male 56% Stage III IV 52% 48% B symptoms 62% Bulk (> 10 cm) 18% IPS % 51% No Radiotherapy Press OW, et al: J Clin Oncol, 2016
42 US Intergroup S0816 trial: Results Median follow up 39.7 months escbeacopp x6 after positive PET-2 improves PFS compared to historical controls Press OW, et al: J Clin Oncol, 2016
43 Single agent brentuximab highly active in upfront treatment of patients age 60 Median follow up: 17 months Median age: 78 ORR: 92%, CR: 73% Median DOR: 9.1 months Median PFS: 10.5 months Peripheral neuropathy All grades: 89% Grade 3: 30% Forero-Torres A, et al. Blood 126: , 2015
44 A + AVD in untreated advanced HL n = 25 BV + ABVD associated with increased pulmonary AEs Median 5 year follow up n = 26 Connors, JM, et al. Blood 2017
45 A + AVD x 4 + RT in early stage unfavorable patients PFS by intention to treat (n = 30) Median follow up 18.8 months 1-year PFS 93.3% Kumar A, et al: Blood 128: , 2016 Current cohorts using lower dose of ISRT (20 Gy) or conformational volume radiotherapy (CVRT, 30 Gy)
First Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationPan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 1: Hodgkin Lymphoma
Pan-London Haemato-Oncology Clinical Guidelines Lymphoid Malignancies Part 1: Hodgkin Lymphoma September 2018 CONTENTS Contents 1 Introduction... 3 2 Referral Pathways from Primary Care... 3 3 Investigation
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationResponse Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy
Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationPrinted by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationFirst line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented
[Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationHodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationEmerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma
Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma Presented as a Live Webinar Thursday, October 26, 2017 1:00 2:00 p.m. ET On-demand Activity Live webinar recorded and archived to be
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationRadiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin
COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationAdvances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationLymphoma update: turning biology into cures. Peter Johnson
Lymphoma update: turning biology into cures Peter Johnson Selected highlights of recent research 1. Using FDG-PET to modify treatment and avoid long term toxicity in Hodgkin lymphoma 2. Understanding how
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationOne, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.
Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.
More informationEnd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma
original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky
More informationGruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo
Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera
More informationLimited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment
HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of
More informationFDG-PET/CT in the management of lymphomas
FDG-PET/CT in the management of lymphomas Olivier Gheysens, MD, PhD Dept. of Nuclear Medicine, UZ Leuven BHS, Feb 4th 2017 Brussels Dept. of Nuclear Overview Introduction on FDG-PET/CT Staging Response
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationSerum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationWhatdidwelearnfromthe H10 trial? M. André
Whatdidwelearnfromthe H10 trial? M. André The H10 EORTC/LYSA/FIL randomized Intergroup trial on early FDG- PET scan guided treatment adaptation versus standard combined modality treatment in patients withsupradiaphragmaticstage
More informationResponse-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Peter W. M. Johnson Cancer Research UK Centre, University of
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre UKONS Conference November 2018 Clinical trials Medical research involving human participants Treatment related New
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Middle East & North Africa (MENA) Edition. Hodgkin Lymphoma
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Middle East & North Africa (MENA) Edition Version 1.2017 May 4, 2017 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients
More informationXVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma
Hematological Oncology Hematol Oncol 2015; 33: 90 95 Published online in Wiley Online Library (wileyonlinelibrary.com).2226 Supplement Article XVIII. Management of nodular lymphocyte predominant Hodgkin
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationNIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Pharmacother. 2010 December ; 11(17): 2891 2906. doi:10.1517/14656566.2010.515979. Hodgkin s Lymphoma Therapy: Past, Present,
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group
Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random
More informationLymphoma. ASTRO Refresher Course 2018: Rahul R. Parikh, M.D.
ASTRO Refresher Course 2018: Lymphoma Rahul R. Parikh, M.D. Department of Radiation Oncology Rutgers Cancer Institute of New Jersey Saturday, March 3 rd, 2018 No conflicts of interest to disclose. Disclosures
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationLate relapse of Hodgkin s lymphoma is it different in clinical characteristics and outcome?
JBUON 2017; 22(2): 481-486 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Late relapse of Hodgkin s lymphoma is it different in clinical characteristics
More informationASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center
ASTRO Refresher Course 2015 Lymphoma Chris Kelsey, M.D. Duke University Medical Center Disclosure Varian Medical Systems Research funding for lung cancer trial Learning Objectives Awareness of Deauville
More informationUpdate in Pediatric Hodgkin Lymphoma
Update in Pediatric Hodgkin Lymphoma Jeff Deyo, MD, PhD Medical Director, Baton Rouge Affiliate St Jude Children s Research Hospital Our Lady of the Lake Children s Hospital Acadiana Potpourri, August
More informationLymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Published Ahead of Print on September 12, 211 as 1.12/JCO.211.36.473 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.473 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationThe Present: Optimizing Therapy Too Much or Too Little?
CLINICAL ADVANCES IN HODGKIN LYMPHOMA The Present: Optimizing Therapy Too Much or Too Little? Nancy L. Bartlett 1 1 Siteman Cancer Center, Washington University, St. Louis, MO Despite the use of less toxic
More information